Trials / Unknown
UnknownNCT05446935
Intrathoracic Chemotherapy for TETs With Pleural Spread or Recurrence
Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy for the Treatment of Thymic Epithelial Malignancies With Pleural Spread or Recurrence (CHOICE): a Prospective, Open, Single-arm Study Choice
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 16 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Hyperthermic intrathoracic chemotherapy (HITOC) offers an additional treatment option for malignant pleural tumors after surgical cytoreduction. Especially it is used to further improve local tumor control in thymic malignancies with pleural spread, who underwent multimodality therapy including surgical resection. A phase II clinical study was conducted to explore the efficacy and safety of surgery followed by HITOC (POD1: DOX, POD2: cisplatin) for thymic epithelial tumors with pleural spread or recurrence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | HITOC | Doxorubicin(dose: 25mg/m2) + Cisplatin(dose: 50mg/m2). |
Timeline
- Start date
- 2022-10-01
- Primary completion
- 2024-11-30
- Completion
- 2025-11-30
- First posted
- 2022-07-07
- Last updated
- 2022-09-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05446935. Inclusion in this directory is not an endorsement.